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Early diagnosis of congenital hypothyroidism (CH) is important because it is one of the most common preventable causes of mental retardation [1]. Most cases 
of CH are sporadic and occur in one in 3000–4000 infants [2]. 
The multicentric study screening above 1 lakh neonates born 
throughout India launched by Indian Council of Medical 
Research (ICMR) National Task Force Team on Newborn 
Screening at All India Institute of Medical Sciences New Delhi 
(2007–2012) reveals a much higher incidence of CH all over 
India at 1 in 1172, particularly in South Indian population 
(1 in 727) [3]. Hypothyroidism in newborns is often overlooked 
as most of them with CH have normal appearance without any 
physical signs. This emphasizes the need for newborn screening 
for hypothyroidism [4].
CH includes subclinical CH and is a generic term for 
congenital thyroid hormone deficiency due to a morphological 
abnormality or dysfunction of the thyroid gland that develops 
in the fetal or perinatal stage. Subclinical CH has no symptoms, 
i.e., it is a subclinical disease, but some patients may have a low 
thyroid hormone level [5].
Most of the newborn screening programs recommend to 
measure thyroid-stimulating hormone (TSH) levels initially 
followed by T4 levels, if TSH levels are elevated. The optimal 
time for screening is 48–72 h of age. This is to minimize the 
false positive high values due to the physiological neonatal TSH 
surge that elevates TSH levels and causes dynamic T4 and T3 
changes in the first 1 or 2 days after birth. Furthermore, for infants 
<1500 g birth weight, repeat specimens should be sent at 2, 6, and 
10 weeks of age due to risk of delayed TSH elevation [6].
Many screening programs using TSH levels above 
20–25 mIU/L recall neonates [2]. TSH levels >50 mIU/L 
are most likely to have permanent CH, whereas a TSH level 
ABSTRACT
Background: Newborn screening for hypothyroidism is necessary because of the high incidence of congenital hypothyroidism 
(CH) in various studies. The necessity of doing confirmatory tests with screening thyroid-stimulating hormone (TSH) levels as 
low as 10 mIU/L is still unclear. Objectives: To find out the incidence of CH as well as its association with screening TSH levels 
between 10 and 20 mIU/L. Materials and Methods: In a prospective observational study, inborn neonates irrespective of their 
gestational age were enrolled and screened for CH using venous TSH levels. Those with TSH levels ≥10 mIU/L were subjected to 
confirmatory tests (free T4 and TSH levels) for the diagnosis based on the recommendations of the Indian Society for Pediatric and 
Adolescent Endocrinology. The various characteristics of the neonates such as birth weight, gender, gestational age, and maternal 
thyroid status were recorded and their relationship with subsequent CH was studied. The association between screening TSH 
levels 10–20 mIU/L and CH was also analyzed, and the cutoff point for screening TSH was determined using receiver operated 
characteristic (ROC) curve. Results: A total of 2407 neonates were screened for CH, out of which 357 (14.8%) were retested with 
free T4 and serum TSH levels. The incidence of CH was 1 in 160.5 (6.2/1000 live births). The male to female ratio was 1.5:1. There 
was a significant association between screening TSH levels and CH. A total of 0.6% of neonates diagnosed with CH had screening 
TSH levels in the range of 10–20 mIU/L, but this association was not found to be statistically significant, and the ideal cutoff value 
was 19.45 mIU/L based on ROC curve. Conclusion: The incidence of CH is high which upholds the need for universal newborn 
thyroid screening. Although there is no statistically significant association between CH and screening TSH levels 10–20 mIU/L, a 
few cases are likely to be missed on using a higher screening TSH cutoff value of 20 mIU/L.
Key words: Congenital hypothyroidism, Incidence, Newborn screening, Screening thyroid-stimulating hormone levels
Jacob et al. Screening TSH levels of 10–20 mIU/L to detect congenital hypothyroidism
Vol 6 | Issue 8 | August 2019 Indian J Child Health 432
between 20 and 49 mIU/L is frequently a false positive or 
represents transient hypothyroidism [2]. In a survey of pediatric 
endocrinologists, infants with TSH ≥10 mIU/L at <6 months 
after birth (excluding neonates) and those with TSH ≥5 mIU/L 
at 12 months after birth were considered to have abnormalities 
(morphological abnormalities such as aplasia, hypoplasia, and 
dyshormonogenesis) to require treatment [5]. However, there are 
no global criteria for the range of abnormal TSH, and diagnosis 
depends on the discretion of the clinician [5]. Patients with 
slightly high TSH may subsequently be diagnosed with persistent 
CH [5]. Therefore, infants in such cases should be very carefully 
followed up from birth.
The TSH cutoff point should be set in a way as to diagnose 
all cases of CH. Considering the deleterious effects of CH which 
is preventable studies need to be done on the incidence of CH 
among newborns with lower TSH levels. This would also aid 
in having an appropriate cutoff point for early diagnosis and 
treatment. The aim of the study was to the assess incidence of CH 
among newborns born in a tertiary care hospital in North Kerala 
and to study the association of CH with screening TSH levels 
10–20 mIU/L.
MATERIALS AND METHODS
After obtaining approval from the Institutional Ethics Committee, 
this hospital-based prospective observational study was conducted 
in the newborn unit of Government Medical College, Kannur, 
over a period of 13 months from August 2017 to August 2018. 
All inborn neonates irrespective of the period of gestation were 
included. Babies who expire or were/referred to another hospital 
before 48 h of life were excluded from the study. Samples were 
collected using consecutive sampling design.
Venous blood was drawn from the study subjects after 48 h of life 
and analyzed for serum TSH levels after getting informed consent 
from the parents. Serum TSH level was analyzed in the certified 
laboratory of the hospital by chemiluminescent immunoassay. 
Babies with TSH levels above 10 mU/L were retested for free 
T4 and TSH levels within 2 weeks and if TSH remained above 
10 mIU/L babies were recalled after 21 days of age for repeat 
testing. The diagnosis was based on consensus guidelines of 
the Indian Society for Pediatric and Adolescent Endocrinology 
[7]. If venous TSH levels were ≥10 mIU/L after 3 weeks of age, 
treatment was started even if free T4 concentrations were normal. 
If free T4 levels were low (<1.1 ng/dl) irrespective of TSH or if 
free T4 <1.17 ng/dl with TSH >20 mIU/L (TSH >10 mIU/L for 
age >2 weeks), then also treatment was started immediately.
The characteristics of newborn infants such as birth weight, 
period of gestation, gender, maternal thyroid status, and their 
relation with CH were studied. The association between CH and 
screening TSH levels was analyzed using Fischer’s exact test and 
Chi-square test. p<0.05 was considered significant. The receiver 
operated characteristic (ROC) curve was used to determine the 
cutoff point and sensitivity of screening TSH.
RESULTS
During the current study over a period of 13 months, 2407 newborn 
babies were screened for CH after 48 h of life. The mean age of 
screening was 3.25±0.74 days. There were 357 babies (14.8%) 
with serum TSH ≥10 mIU/L who were retested with serum-free 
T4 and TSH levels within 2 weeks. The mean TSH levels of the 
retested neonates were 15.76±12.62 (10–100). Out of 357 of the 
retested neonates, 219 (61.3%) were males and 138 (38.7%) were 
females. The mean birth weight and mean gestational age were 
2.61±0.62 kg and 37.01±2.43 weeks, respectively. Screening 
characteristics of retested neonates are presented in Table 1.
There was a significant association between screening TSH 
levels and CH (using Fisher’s exact test, p<0.001). Incidence of CH 
in the present study was 0.62%, i.e., 6.2 per 1000 live births (1 in 
160.5). Among neonates with CH, 9 (60%) were males and 6 (40%) 
were females (male: female ratio 1.5:1). Of the CH cases, 10 were 
full term (66.7%) and 5 (33.3%) were preterm infants among which 
2 (13.3%) were between 28 and 34 weeks and 3 (20%) were in 
the 34 and 37 weeks category. The birth weight was normal in 
10 (66.7%) neonates, 2 (13.3%) had very low birth weight, and 
3 (20%) had low birth weight. There was no statistical association 
between birth weight or gestational age and hypothyroidism. In two 
neonates (13.3%) with CH, mother had hypothyroidism, but there 
was no statistical association. The proportion of retested neonates 
diagnosed as CH based on screening TSH levels is given in Table 2.
The area under the curve level for screening TSH ≥10 mIU/L 
according to the confirmatory thyroid function tests, free T4 and 
TSH (gold standard) was 0.960 (Fig. 1). Based on ROC curve, 
the appropriate cutoff point for retesting for screening TSH with 
acceptable sensitivity and specificity was 19.455. The sensitivity 
and specificity for determined cutoff point (19.455) were 93.3% 
and 90.1%, respectively. The sensitivity and specificity of various 
TSH cutoff values between 10 and 20 mIU/L are given in Table 3.
Table 1: Screening characteristics of the retested neonates
Variables Number (%)
Birth weight (g)
≥2500 231 (64.7)
1500–2500 104 (29.1) 
1000–1500 15 (4.2)
<1000 7 (2)
Gestational age (weeks)
Term (≥37) 228 (63.9)
34–37 94 (26.3)
28–34 27 (7.6)
<28 8 (2.2)
Sex
Male 219 (61.3)
Female 138 (38.7)
Maternal thyroid status
Normal 324 (90.7)
Hypothyroidism 30 (8.4)
Hyperthyroidism 3 (0.8)
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Of the 15 cases diagnosed as CH, free T4 levels were low 
with TSH levels >20 mIU/L in 12 cases. Normal FT4 and 
TSH 10–20 mIU/L were seen in 1 case and when retested after 
21 days of age was confirmed to have CH (low FT4 and TSH 
>20 mIU/L). Two babies had normal FT4 and TSH >20 mIU/L 
who also on retesting after 21 days of age showed low FT4 and 
TSH >20 mIU/L and were put on treatment. None of the babies in 
the study had low free T4 levels alone (<1.1) as per consensus to 
diagnose CH. The thyroid hormone levels of the cases diagnosed 
are shown in Table 4.
DISCUSSION
The overall objective of the study was to find out the incidence 
of CH among babies admitted in Government Medical College, 
Kannur, and to know if those babies with screening TSH between 
10–20 mIU/L need to be retested for diagnosing CH as against 
the conventional practice of retesting those with levels above 
20 mIU/L.
The incidence of CH in the present study is 1 in 160.5 among 
inborn infants. Recent Indian studies have suggested a high 
incidence of CH. Desai et al. reported 1 in 2640 in 1997 [8]. 
Other studies have reported the incidence as 1 in 1700 neonates 
from Hyderabad, 2.1 in 1000 from Kochi, and  1 in 1042 in 
another study recently from Bangalore (instead of UP) [9-11]. 
All these data show a high prevalence which further implies 
better screening strategies with accessibility and probably iodine 
deficiency in mothers which require further studies to make an 
authentic statement. The variable results in the studies could be 
due to the variation in sample sizes and the inclusion of preterm 
infants in the sample in some studies.
The female to male sex ratio of CH in the study was 1:1.5, and 
gender was not a significant risk factor for the occurrence. This is 
in accordance with a study from Iran reporting a female to male 
ratio of 1:1.4 [12]. A recent meta-analysis found CH incidence 
of 1.35 (95% confidence interval: 0.99, 1.83) with significant 
heterogeneity among studies and a higher risk in girl gender 
which is in sharp contrast to our study [13]. This difference might 
be due to small sample size in our study.
We found no significant association between CH and other 
variables such as birth weight, gestational age, and maternal 
hypothyroidism. The study from Iran shows a similar picture [12]. 
Although not statistically significant, maternal hypothyroidism was 
present in 13.3% of neonates diagnosed with CH. This emphasizes 
the need for screening mothers for hypothyroidism and to conduct 
further studies to determine the role of genetic factors in CH.
We used the screening TSH cutoff of 10 mIU/L and 357 out of 
2407 neonates (14.8%) had to be retested. The retest rate was 14.8% 
using a screening TSH cutoff of ≥10 mIU/L. Using this cutoff, 
15 cases were diagnosed (4.2%) as CH and were started on treatment 
with levothyroxine. Of these, 315 (88.2%) had TSH 10–20 mIU/L 
and 42 (11.8%) had TSH ≥ 20 mIU/L. Of the 315 cases with 
Table 3: Sensitivity and specificity of screening TSH cutoff values
Screening TSH cutoff  
(mIU/L) 
Sensitivity (%) Specificity (%)
10.02 100 26
13.52 100 65.2
15.02 93.3 73.7
19.45 93.3 90.1
TSH: Thyroid-stimulating hormone
Table 4: Thyroid hormone profile in newborns with congenital 
hypothyroidism
Screening 
TSH (mIU/L)
FT4 (ng/dl) and 
TSH (mIU/L)
FT4 and TSH 
at 21 days
10–20
19.74 1.9, 10.7 1.4, 34.4
13.6 1.18, 20.2
>20
26.7 1.6, 24.08
45.3 1, 72.5
29 1.8, 37.95 1.5, 35
22.01 1.6, 24.9
82.6 1.5, 100
>100 0.96, >100
24.46 1.7, 30.2 1.4, 43.9
21.29 0.122, >100
>100 1.19, >100
>100 0.25, >100
>100 0.57, >100
>100 1.06, 96.69
>100 1.1, >100
TSH: Thyroid-stimulating hormone
Table 2: Congenital hypothyroidism and screening TSH levels
Screening TSH (mIU/L) CH (%) No CH (%) Total
10–20 2 (0.6) 313 (99.4) 315
≥20 13 (31) 29 (69) 42
Total 15 342 357
CH: Congenital hypothyroidism, TSH: Thyroid-stimulating hormone
Figure 1: Area under the curve (AUC) level for screening 
TSH ≥ 10 mIU/L 
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screening TSH 10–20 mIU/L, 2 cases (0.6%) were subsequently 
diagnosed to have CH, and there was no statistical association.
The screening TSH cutoff value of 10 mIU/L in the current 
study detected 15 cases of CH with a sensitivity of 100% and 
specificity of 26% based on the ROC curve. At the TSH cutoff 
value of 13.52, the specificity increased to 65%. The ideal cutoff 
in the present study was 19.45, with a sensitivity of 93.3%. Since 
sensitivity is more important for a screening test, it is prudent 
to have a high index of suspicion with close follow-up for TSH 
values at least above 13 mIU/L. If a higher TSH cutoff value of 
20 mIU/L been used, 2 of the confirmed cases (13.3%) would 
have been missed. In a Brazilian study where the prevalence 
of CH was 1:2234, a screening TSH cutoff value of 5 mIU/L 
detected 50 cases of CH with a sensitivity of 100% [14]. Botler 
et al. analyzed various TSH cutoff values for detecting CH and 
42 cases were found using a cutoff value of ≥20.0 mIU/L in 2005, 
but 165 cases were found in 2007 when the cutoff value was 
reduced to ≥10.0 µIU/mL [15]. Korada et al. detected 120 infants 
with CH using a TSH cutoff value of 6.0 mIU/L [16].
In an Italian study, a screening TSH cutoff of <15 mIU/L was 
used, and it was found that among those diagnosed with CH with 
screening TSH values below 15 mIU/L, 21.6% had permanent 
hypothyroidism and 54% had transient hypothyroidism [17]. In a 
study done in preterm infants of 21–35 weeks, a lower cutoff of 
6 mIU/L was used and it was concluded that using such a lower 
cutoff in preterm infants, CH could be diagnosed earlier and 
repeat testing could be avoided at 36 weeks since they usually 
exhibit a delayed TSH rise [18]. A study by ICMR task force in 
infants of 34 weeks and above recommends that 10 mIU/L is 
the 97.5th percentile value even when corrected for gender, birth 
weight and age at sampling and thus 10 mIU/L seems to be the 
right cutoff beyond which a second sample should be sought [19].
This study reinforces the fact that CH is highly prevalent in 
our population and that a vigilant eye with meticulous screening 
is needed to pick up the cases. Many studies mentioned above 
reported the occurrence of CH in newborns with lower screening 
TSH levels. Considering the high incidence of CH in the area 
as found in the present study, accepting a sensitivity of 100% 
and specificity of 65% for a screening TSH cutoff value of 
13.52 mIU/L seems justifiable.
The main limitation of our study was a small sample size. Larger 
sample size would have been needed to get a statistical association 
between TSH levels 10–20 mIU/L and CH. Further studies on a 
larger population are necessary to eliminate this gray area. Another 
limitation was that we did not categorize neonates into preterm 
and terms which might be the reason for the heterogeneity in the 
incidence of CH when compared to other Indian studies.
CONCLUSION
The high incidence of CH in this study corroborates the need for 
universal screening of newborns. The occurrence of CH in babies 
with screening TSH levels 10–20 mIU/L though in a smaller 
proportion raises the question whether the cutoff of screening 
TSH should be brought down to a lower level. More studies on a 
larger sample are needed to hit on a solution.
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